Autolus Therapeutics plc

Total net product revenue in Q2 2026 was $45.7 million, versus $20.9 million in Q2 2025 and $26.2 million in Q1 2026. Gross margin improved to 55% from 6% in Q1 and from negative margins in all prior quarters of 2025. Cost of sales was $20.5 million, down from $24.4 million a year ago; R&D was $27.9 million versus $27.4 million; SG&A was $41.2 million versus $30.3 million. Loss from operations was $43.8 million, and net loss was $39.1 million, compared with $61.2 million and $47.9 million, respectively, a year ago. Full-year AUCATZYL net product revenue guidance was raised to $140 million-$150 million. Management said gross margin should continue improving toward 65%-70% in the adult ALL market, and cash, cash equivalents and marketable securities were $201.6 million at June 30, 2026; including expected revenues and the first and second tranches of the credit facility, runway extends into Q2 2028.

Christian Itin described the quarter as very positive and emphasized that the launch is building momentum in both the U.S. and the newly launched U.K. market. He repeatedly framed the business as moving from launch execution to operational optimization, with more than 80 centers now active and additional centers being added in the second half. He also positioned the company as having multiple future catalysts beyond adult ALL, including pediatric ALL, lupus nephritis, progressive MS, and light-chain amyloidosis.

Robert Dolski highlighted the main financial improvements: revenue of $45.7 million, gross margin of 55%, lower cost of sales at $20.5 million, and a narrower net loss of $39.1 million. He tied the margin gains to higher commercial production volume, operating-model efficiency, cost reduction actions, and the first clinical production in the Nucleus facility, and he reiterated that gross margin should trend toward 65%-70%. He also detailed the financing with Perceptive Advisors, noting an initial $75 million draw, a further $25 million optional tranche within six months, and up to $150 million more tied to revenue milestones, which together support runway into Q2 2028.

Analysts focused on whether Q2 revenue set a high bar for the rest of the year, and management said seasonality may create quarter-to-quarter fluctuations but that guidance includes prudence. On margins, management said the step-up to 55% was driven by higher batch volume, clinical production consolidation into Nucleus, and operational changes, with the 65%-70% target expected in about 12-18 months. Questions also covered center activation, with management saying most of the more than 80 activated sites have already treated patients, and U.K. launch traction, where they expect around 20 centers by year-end and said the market is still early.